Analyst Ratings For Amicus Therapeutics (NASDAQ:FOLD)
Today, Leerink Swann raised its price target on Amicus Therapeutics (NASDAQ:FOLD) to $24.00 per share.
Some recent analyst ratings include
- 1/10/2018-Cowen Reiterated Rating of Buy.
- 10/6/2017-Goldman Sachs Group Reiterated Rating of Neutral .
- 10/5/2017-Chardan Capital Reiterated Rating of Buy.
- 10/4/2017-JPMorgan Chase & Co. Reiterated Rating of Overweight.
- On 12/29/2018 John F Crowley, CEO, sold 5,920 with an average share price of $14.75 per share and the total transaction amounting to $87,320.00.
- On 1/23/2018 Jay Barth, Insider, sold 20,000 with an average share price of $16.80 per share and the total transaction amounting to $336,000.00.
- On 1/22/2018 Bradley L Campbell, COO, sold 32,500 with an average share price of $15.92 per share and the total transaction amounting to $517,400.00.
- On 1/2/2018 Daphne Quimi, SVP, sold 8,000 with an average share price of $14.72 per share and the total transaction amounting to $117,760.00.
- On 1/2/2018 Donald J Hayden Jr, Director, sold 20,000 with an average share price of $15.00 per share and the total transaction amounting to $300,000.00.
- On 1/2/2018 Jay Barth, Insider, sold 5,000 with an average share price of $14.71 per share and the total transaction amounting to $73,550.00.
- On 1/2/2018 William D Baird III, CFO, sold 10,000 with an average share price of $14.72 per share and the total transaction amounting to $147,200.00.
Recent Trading Activity for Amicus Therapeutics (NASDAQ:FOLD)
Shares of Amicus Therapeutics closed the previous trading session at 15.42 down -1.46 8.65% with 15.367400169372559 shares trading hands.